Trazodone vs. Dayvigo

See how Trazodone and Dayvigo compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Trazodone is FDA-approved only for major depressive disorder, so using it for sleep is an off-label practice guided by a doctor's judgment, not an FDA-approved use.

  • Dayvigo is FDA-approved specifically for insomnia and works by blocking wake-promoting orexin signals instead of boosting GABA activity like older sleep drugs.

  • Trazodone is a low-cost generic with decades of use, while Dayvigo is newer, brand-only, and a Schedule IV controlled substance.

Trazodone vs. Dayvigo Drug Summary

Trazodone

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that is FDA-approved to treat major depressive disorder in adults. It is not FDA-approved for insomnia, but it is widely prescribed off-label at lower doses to help people fall asleep. It comes as an oral tablet, usually taken once nightly for sleep or in divided doses for depression.

Dayvigo

Dayvigo (lemborexant) is a dual orexin receptor antagonist FDA-approved to treat insomnia in adults who have trouble falling asleep, staying asleep, or both. It is taken as a single 5 mg or 10 mg tablet each night, shortly before bed.

Trazodone vs. Dayvigo Side Effects

Trazodone

Most common
Drowsiness (up to 41%)
Dry mouth (up to 30%)
Dizziness (up to 28%)
Headache (up to 20%)

Dayvigo

Most common
Somnolence (up to 10%)
Headache (up to 6%)
Diarrhea (up to 3%)
Nasopharyngitis (up to 3%)

Trazodone vs. Dayvigo Dosage

Trazodone

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 25 mg nightly At the start
Maximum dose Up to 150 mg nightly If needed
Dose changes 3 increases As tolerated

Dayvigo

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once nightly At the start
Maximum dose 10 mg once nightly If needed
Dose changes 1 increase As tolerated

Trazodone vs. Dayvigo Indications

Trazodone

Trazodone's only FDA-approved use is major depressive disorder in adults, at doses much higher than those typically used for sleep. Using it for insomnia is off-label, meaning the FDA has not evaluated or approved it for that purpose, even though many doctors prescribe it this way at lower doses.

  • Major depressive disorder (FDA-approved)

  • Insomnia (off-label use only)

  • Often added to an SSRI for sleep (off-label)

  • Used off-label in patients with substance use risk

Dayvigo

Dayvigo is FDA-approved specifically for adults with insomnia, covering trouble falling asleep, staying asleep, or both. It is not approved for children or for narcolepsy, and its benefit has been studied with nightly use for up to 12 months.

  • Insomnia with difficulty falling asleep

  • Insomnia with difficulty staying asleep

  • Studied for nightly use up to 12 months

  • Not approved for narcolepsy or children

Trazodone vs. Dayvigo Pros and Cons

Trazodone

Trazodone's safety profile comes from depression trials at higher doses, not from studies designed around sleep, so its off-label use for insomnia relies on clinical experience rather than label guidance. Its low generic price and lack of controlled-substance status make it easy to access.

Pros

  • Roughly $5 to $25 a month as a generic, without insurance or savings programs

  • Not a controlled substance, so no special monitoring or refill limits

  • Decades of real-world use and safety data across many patient types

Cons

  • Not FDA-approved for insomnia, so sleep dosing relies on clinical experience rather than label guidance

  • Carries a boxed warning for increased suicidal thoughts in children and young adults

  • Can cause dry mouth, dizziness from low blood pressure, and next-day grogginess

  • Rare but serious risk of prolonged, painful erections (priapism) in men

Dayvigo

Dayvigo's safety and dosing data come from trials built specifically around insomnia, giving providers evidence matched to that exact use. That more targeted profile comes with a brand-only price and controlled-substance status.

Pros

  • Specifically FDA-approved for insomnia, with dosing built for sleep rather than adapted from another use

  • 12-month trial data show sustained benefit without rebound insomnia after stopping

  • Works by blocking wake-promoting orexin receptors, a different mechanism than GABA-based sleep drugs

Cons

  • Roughly $135 to $400 a month, since no generic version exists yet

  • Schedule IV controlled substance with potential for misuse and dependence

  • Warning for complex sleep behaviors such as sleep-walking or sleep-driving

  • Not approved for use in children or for narcolepsy

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.